ArticleAmerican journal of translational research2025
Inflammatory cytokines, metabolites, and pre-eclampsia: a two-sample Mendelian randomization study.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolomic Profiles of Inflammation Associated With Incident Ischemic Stroke Risk in Women.Neurology · 2026Article
- Fractalkine (Chemokine CX3CL1) Signaling During Placentation and Placental Function.International journal of molecular sciences · 2026Review
- Association of early-pregnancy platelet-to-high-density lipoprotein cholesterol ratio with preeclampsia: a retrospective cohort study.American journal of clinical and experimental immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPre-eclampsia (PE) is a leading cause of maternal and fetal mortality, with inflammatory dysregulation implicated in its pathogenesis. This Mendelian randomization (MR) study aimed to investigate the causal effects of 91 inflammatory cytokines on PE and to identify potential mediating metabolites.
methodsWe conducted a two-sample MR analysis using genome-wide association study data from European-ancestry populations: including 91 inflammatory cytokines (14,824 participants), 1,400 plasma metabolites (8,299 participants), and PE (2,355 cases; 264,887 controls). Instrumental variables were selected at P < 1 × 10
resultsWe identified two novel risk factors and two protective factors for PE: genetically proxied elevations in fibroblast growth factor 5 (FGF-5) and Matrix metalloproteinase-1 (MMP-1) increased PE risk, whereas interleukin-10 (IL-10) and interleukin-20 (IL-20) were protective. Importantly, this is the first MR study to identify N-acetyl-L-alanine (ALA) as a significant mediator of cytokine effects in PE. ALA mediated 5.56% of the effect of FGF-5, revealing a pathway whereby elevated FGF-5 reduces ALA levels and consequently increases PE risk.
conclusionsThis study establishes FGF-5 and MMP-1 as novel causal risk factors for PE, while IL-10 and IL-20 exert protective effects. The identification of ALA as a partial mediator of FGF-5 uncovers a new metabolic-inflammatory pathway in the pathogenesis of PE. These findings highlight potential biomarkers and therapeutic targets for the prevention and treatment of PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.